https://www.businesswire.com/news/home/20220615005625/en/
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.
The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.